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Resumo 
 
 
A hipertensão pulmonar (HP), é uma doença multifactorial e progressiva, 
caracterizada pela vasoconstrição, remodelação vascular pulmonar e trombose 
in situ, com consequente aumento da pressão arterial pulmonar e da 
resistência vascular pulmonar, frequentemente culminando na insuficiência 
cardíaca direita e morte. A remodelação vascular pulmonar, um dos principais 
contribuintes para o desenvolvimento e progressão da HP, é caracterizada por 
uma proliferação celular excessiva e uma reduzida apoptose. No entanto, 
pouco se sabe sobre os mecanismos moleculares subjacentes a este 
desequilíbrio. Assim, o presente trabalho teve como objetivo principal a 
avaliação da contribuição da apoptose na patogénese da HAP, através da 
análise da expressão cardíaca e pulmonar da survivina e do Smac/DIABLO e a 
sua associação às alterações hemodinâmicas e morfométricas. Para o efeito 
utilizou-se um modelo animal de HAP induzida por administração de 
monocrotalina (MCT). Os resultados demonstraram que os cardiomiócitos se 
encontravam hipertrofiados 7 dias após a injeção de MCT o que precedeu as 
alterações hemodinâmicas que se verificaram apenas ao dia 21. Sete dias 
após a administração de MCT observou-se sobreexpressão de survivina nos 
ventrículos, tendo esta aumentado progressivamente com a doença. A nível 
pulmonar, embora sobreexpressa ao dia 7, a expressão de survivin diminuiu 
com o desenvolvimento da doença. Apesar de sobreexpressa nos ventrículos 
e no pulmão 7 dias após injeção de MCT, a expressão do Smac/DIABLO 
diminuiu progressivamente com a HAP. Em conclusão, os resultados sugerem 
que a desregulação das vias de sinalização nas quais intervêm a survivina e o 
Smac/DIABLO está relacionada com a remodelação vascular pulmonar e a 
hipertrofia dos cardiomiócitos em resposta a estímulos apoptóticos. 
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Abstract 
 
Pulmonary hypertension (PH) is a multifactorial, progressive disease, 
characterized by vasoconstriction, pulmonary vascular remodelling and 
thrombosis in situ, which lead to augmentation of pulmonary arterial pressure 
and pulmonary vascular resistance, culminating in right heart failure and 
ultimately in dead. Pulmonary vascular remodelling, which is one of the major 
contributors to the development and progression of PH, is characterized by 
excessive cellular proliferation and reduced apoptosis. However, little is known 
about the molecular mechanisms underlying this imbalance. So, the present 
work aimed to study the contribution of apoptosis to the pathogenesis of PAH, 
through the analysis of cardiac and pulmonary expression of survivin and 
Smac/DIABLO along hemodynamic and morphometric alterations in an animal 
model of monocrotaline (MCT)-induced PAH. Results showed that 
cardiomyocytes were hypertrophied 7 days after MCT injection, preceeding 
hemodynamic alterations which were only present at day 21. Seven days after 
MCT administration, survivin overexpression was notorious in the ventricles 
and progressively increased throughout the development of MCT-induced PAH. 
On the other hand, although increased 7 days after MCT injection, lung survivin 
expression progressively decreased between the two days. The upregulation of 
Smac/DIABLO observed in lung, right and left ventricles 7 days after MCT 
administration, progressively decreased with the disease progression. In 
conclusion, data suggest that a deregulation in the balance between survivin 
and smac/DIABLO might be related with pulmonary vascular remodelling and 
cardiomyocytes hypertrophy in response to apoptotic stimuli. 
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Pulmonary hypertension (PH) has been defined as a sustained elevation of the 
pulmonary arterial pressure (PAP) to more than 25 mmHg at rest or greater than 30 
mmHg with exercise [1]. This is a multifactorial, progressive disease, with substantial 
mortality and morbidity. Besides elevated PAP, PH is characterized by: (i) increased 
pulmonary vascular resistance (PVR); (ii) alterations in the extracellular matrix (ECM); 
(iii) pulmonary vascular remodelling due to proliferation and migration of endothelial 
cells (ECs) and vascular smooth cells; (iv) progressive pulmonary vascular obliteration; 
(v) thrombosis and (vi) fibrosis, frequently leading to right-sided heart failure (HF) and 
death [2]. Untreated patients have a median survival time of 2.8 years [3]. Although it is 
found in both sexes at all ages, it has a higher incidence in women than men (2:1) and 
the average age of presentation is 36 years old [4].  
Over the years the cellular and molecular mechanisms underlying the PH have been 
studied, not only to better understand these alterations, but also to develop therapies that 
may lead to a better prognosis. The therapies implemented at this moment are not 
entirely efficient because although they increase patients’ survival, they do not lead to a 
cure. Therefore, the study of these mechanisms remains essential to better understand 
the development and progression of the disease and to plan a targeted and personalized 
therapy. For that reason, using a monocrotaline (MCT) animal model we studied the 
contribution of apoptosis to the pathogenesis of pulmonary arterial hypertension (PAH), 
through the analysis of the apoptotic proteins survivin and Smac/DIABLO. 
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1. Pulmonary Hypertension: Classification, Risk Factors and Diagnosis 
In 1891, during an autopsy, the German physician Ernst von Romberg observed 
pulmonary vascular lesions without a known cause, which he named “pulmonary 
vascular sclerosis”, a classical description of PH (reviewed in [5]). The term primary 
pulmonary hypertension (PPH) was first used in 1951 after Dresdale and his associates 
reported data on 39 patients with unexplained PH (reviewed in [6]). Due to the rising 
incidence of PH in Europe, in 1973 at an international conference on PPH, World 
Health Organization (WHO) proposed a classification for PH that included two groups: 
PPH, a rare disorder that occurred without a known underlying cause, or secondary PH, 
a disease that developed in the presence of an underlying cause or in the presence of risk 
factors [6]. Later in 1998, this classification was reviewed at the Second World 
Symposium on PAH (Evian, France). In the “Evian Classification” PH was divided into 
five major groups based on pathobiologic and clinical features as well as therapeutic 
options [7]. During this Symposium, different risk factors for PAH: (i) drugs, toxins and 
chemicals (e.g. aminorex, meta-amphetamines, benfluores, cocaine, chemotherapeutic 
agents), (ii) demographic and medical conditions (e.g. gender, pregnancy, obesity), and 
(iii) diseases (HIV infection, thyroid disorders, collagen vascular disease) were 
categorized as definitive, very likely, possible or unlikely according to the strength of 
their association with PH and their probable casual role [7].  
The classification was modified once more in 2003 at the Third World Symposium 
(Venice, Italy). The nomenclature “idiopathic pulmonary arterial hypertension” (iPAH) 
was adopted instead of PPH. In 2008 at the Fourth World Symposium on PH (Dana 
Point, California) (Table 1) the classification of PH was updated, and the term “non-
PAH” was approved for other categories than PAH [8]. Additionally, left-heart disease 
PH was subdivided in systolic HF, diastolic HF and valvular heart disease and 
schistosomiasis was included as a new class of disease-associated PAH [8]. More 
recently, in March of 2013 the Fifth World Symposium was realized in Nice (France), 
however the new guidelines have not been published yet. 
So, nowadays PH is classified in: (i) PAH; (ii) pulmonary veno-occlusive disease 
(PVOD) and/or pulmonary capillary hemangiomatosis (PCH); (iii) PH associated with 
left heart disease; (iv) PH associated with lung disease and/or hypoxia; (v) chronic 
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thromboembolic PH (CTEPH) and (vi) PH with unclear or multifactorial mechanisms 
(Table 1). 
Table 1 | Clinical Classification of Pulmonary Hypertension, from the 4th World Symposium on 
Pulmonary Hypertension (Dana Point, 2008) (adapted from [8]). 
Pulmonary Arterial Hypertension  
Group 1: Pulmonary Arterial Hypertension  
1.1 Idiopathic 
1.2 Familial/Heritable (BMPR2, ALK1, endoglin, unknown) 
1.3 Drugs and toxin-induced 
1.4 Associated with: 
      1.4.1 Connective tissue disease 
      1.4.2 HIV infection 
      1.4.3 Portal hypertension 
      1.4.4 Schistosomiasis 
      1.4.5 Congenital heart disease 
      1.4.6 Chronic haemolytic anaemia 
       1.4.7 Others 
1.5 Persistent pulmonary hypertension of the newborn 
Group 1': Sub-class of Pulmonary Arterial Hypertension 
1'. Pulmonary veno-occlusive disease and/or pulmonary capillary hemangiomatosis 
Non-Pulmonary Arterial Hypertension 
Group 2: Pulmonary Hypertension associated with left heart disease 
2.1 Systolic dysfunction 
2.2 Diastolic dysfunction 
2.3 Valvular disease 
Group 3: Pulmonary Hypertension associated with lung disease and/or hypoxia 
3.1 Chronic obstructive pulmonary disease 
3.2 Interstitial lung disease 
3.3 Sleep-disordered breathing 
3.4 Chronic exposure to high altitude 
3.5 Alveolar hypoventilation disorders 
3.6 Developmental abnormalities 
Group 4: Chronic Thromboembolic Pulmonary Hypertension  
Group 5: Pulmonary Hypertension with unclear or multifactorial mechanisms 
5.1 Hematologic disorders (e.g. Myeloproliferative disorders) 
5.2 Systemic disorders (e.g. vasculalitis, sarcoidosis, neurofibromatosis) 
5.3 Metabolic disorders (e.g. glycogen storage disease, thyroid disorders) 
5.4 Congenital heart disease (other than systemic-pulmonary shunt) 
5.5 Others 
Legend: BMPR2 – bone morphogenetic protein receptor-II; ALK1 – activin receptor-like kinase 1; HIV – human 
immunodeficiency virus 
 
Besides the classification based on pathobiologic and clinic features, patients with PH 
can also be classified according to their functional capacity (Table 2). This classification 
has been adopted from the New York Heart Association (NYHA) for left heart disease 
[9]. Both clinical and functional classifications are useful for diagnosis, prognosis and 
therapy guidance of PH. 
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Table 2 | Functional classification of Pulmonary Arterial Hypertension (adapted from [9]). 
Class I: 
Patients with pulmonary hypertension without resulting in limitation of physical activity. 
 
Normal physical activity does not cause undue dyspnoea or fatigue, chest pain or near 
syncope. 
Class II: 
Patients with pulmonary hypertension resulting in slight limitation of physical activity. 
 
They are comfortable at rest, but normal physical activity causes undue dyspnoea or fatigue, 
chest pain or near syncope. 
Class III: 
Patients with pulmonary hypertension resulting in marked limitation of physical activity. 
 
The patient is comfortable at rest, but less than normal physical activity causes undue 
dyspnoea or fatigue, chest pain or near syncope. 
Class IV: 
Patients with pulmonary hypertension with inability to carry out any physical activity 
without symptoms. 
 
These patient manifest signs of right heart failure. Dyspnoea and/or fatigue may even be 
present at rest. Discomfort is increased by any physical activity. 
 
 
In advanced disease the patient may present non specific symptoms such as: chest pain, 
breathlessness, fatigue, weakness, palpitations, oedema, ascites and syncope [10, 11]. 
After careful examination, the clinician can also found: (i) hepatomegaly, (ii) right 
ventricular hypertrophy (RVH) and right atrial dilation on the electrocardiogram and 
(iii) increased systolic pulmonary artery pressure (SPAP) on the echocardiography [10-
12]. For a differential diagnosis and assessment of disease severity it may be required: 
(i) antinuclear antibodies, (ii) autoimmune disease markers, (iii) HIV and viral hepatitis 
screening, (iv) coagulation disorder markers (e.g. protein S and C, von Willebrand 
factor) and (v) cardiac deterioration markers (e.g. cardiac troponin T, B-type natriuretic 
peptide (BNP)) [11, 12]. 
 
2. Pulmonary Vascular Morphology in Pulmonary Hypertension 
In order to maintain its main function – gas exchange – pulmonary circulation is a low-
pressure, high-flow and low-resistance system. Therefore the walls of the pulmonary 
arteries (PAs) are relatively thin [13]. The pulmonary vascular wall has 3 layers: (i) an 
outer adventitia containing fibroblasts, (ii) a media, composed of smooth muscle cells 
(SMCs) and an elastic lamina (the internal and external, separating the three layers), and 
(iii) an intima, with a single layer of ECs and a basement of connective tissue (Figure 1) 
[13, 14]. 
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Figure 1 | Pulmonary Vascular Morphology. A) The pulmonary vascular wall has 3 layers: an outer 
adventitia, a media and an intima; B) In PH, vascular remodelling is characterized the thickening of all 
three layers of pulmonary vessel wall. 
Pathological changes underlying PH involves vascular remodelling, which is 
characterized by the thickening of all three layers of pulmonary vessel wall due to the 
hypertrophy or hyperplasia of one or more cell types as well as increased deposition of 
ECM components (example: collagens) (Figure 1) [13, 15, 16]. The thickening of media 
(proliferation and hypertrophy of medial smooth muscle) and/or intima (EC 
hypertrophy and hyperplasia, oedema and thickening of the endothelial basement 
membrane) leads to narrowing and occlusion of pulmonary artery, increasing PVR and 
PAP [13, 15, 16]. In the adventia layer is also seen the proliferation of fibroblasts and 
the deposition of collagen [16]. 
 
 
 
 
In severe stages of PH occurs the formation of a layer of ECM and cells (SMCs or 
myofibroblasts embedded in mucopolysaccharide) between the internal elastic lamina 
and the endothelium – neointima – which also contribute to the elevation of PVR [13, 
17]. These myofibroblasts express markers such as α-smooth muscle actin and vimentin 
but there is no expression of smooth muscle myosin (characteristic marker of highly 
differentiated SMCs), cluster of differentiation 31 (CD31), CD34 or factor VIII (ECs 
markers) [17]. Plexiform lesions, another form of vascular remodelling, also 
predominates in severe stages of PH. They occur due to the disorganised proliferation of 
ECs supported by a myofibroblast stroma, contributing to the elevation of PVR [13, 18]. 
These ECs express angiogenic markers such as vascular endothelial growth factor 
(VEGF) and its receptors [19, 20]. In some forms of PH the release of reactive oxygen 
species (ROS), growth factors, cytokines and angiogenic factors from the abundant mast 
cells, T and B lymphocytes and macrophages that surround PAs and arterioles may play 
a role in vascular remodelling [18]. With time, all of these vascular remodelling events 
lead to the reduction of PAs’ lumen due to its obliteration, resulting in PVR rise and 
PAP elevation. The augmentation of the PVR results in an overwork of the heart 
especially of the right ventricle (RV) inducing RVH [21]. Muscle mass accumulates in 
the RV (through the enhancement of protein synthesis and myocyte hypertrophy) 
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increasing wall thickness, and it assumes a more rounded shape compressing the left 
ventricle (LV) [21, 22]. Although in an initial phase the overwork of the RV can 
maintain the cardiac output, the persistent elevated resistance leads to a progressive 
dysfunction that frequently culminate in right heart failure [21]. 
 
3. Pathobiology of Pulmonary Hypertension 
3.1. Genetic Associations 
Mutations in bone morphogenetic protein (BMP) receptor 2 (BMPRII), and single 
nucleotide polymorphisms of KV (voltage-gated K
+
 channels) 1.5, transient receptor 
potential (TRP) channels and serotonin transporters (SERT) have been implicated in the 
development of PH. 
Bone morphogenetic proteins (BMPs) are multi-functional growth factors that belong to 
the transforming growth factor (TGF) superfamily. They have multiple important roles 
in vascular remodelling, including inhibition of apoptosis and SMC proliferation, 
regulation of vasoactive peptides and growth factors, and modulation of immune cell 
function [23]. Signalling pathways involving BMPs involve the formation of hetero-
complexes between one of type-I receptors and one of type-II receptors [24]. The TGF-
β superfamily type II receptors are constitutively active serine/tyrosine kinases that 
initiate intracellular signalling in response to specific ligands [24]. After BMP binding, 
type-II receptor phosphorylates type-I receptor, activating its kinase domain [24, 25]. In 
turn, activated type-I receptor phosphorylates the cytoplasmic signalling proteins 
responsible for TGF-β superfamily signal transduction – Smad – that translocates to the 
nucleus where interacts with various transcription factors, regulating gene transcription 
(e.g. Bcl-2 and K
+
) [24, 25]. There is evidence that MAPKs (mitogenic-activated 
protein kinase), including ERKs (extracellular-signal-regulated kinase), p38, and JNKs 
(c-Jun N-terminal kinases) might also be activated via TGF-β and BMPs [24-26]. 
Mutations in the gene coding for BMPRII (locus in chromosome 2q31-32) have been 
found in more than 70% of familiar PAH, and 10% to 40% in iPAH [27]. In spite of the 
autosomal dominant inheritance of BMPRII gene mutations, this disease has a low 
penetrance since only approximately 20% of individuals carrying the mutation will 
develop PAH [27]. One hundred and forty four mutations in BMPRII have been 
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reported until now, particularly missense mutations that lead to substitution of cysteine 
residues in the ligand-binding and/or kinase domain of BMPRII, which culminate in the 
traffic disruption of the mutant BMPRII to the cell surface retaining the receptor in the 
cytoplasm [28, 29]. On the other hand, in non-cysteine missense mutations in the kinase 
domain, BMPRII mutants reach the cell surface but fail to activate Smad either by 
disruption of its serine-threonine kinase activity or the inability to complex with type I 
receptors [28]. In addition, missense mutations in the cytoplasmic domain attained the 
cell surface and retained the ability to activate Smad signalling [28]. All these mutations 
will result in a common feature – gain of function ligand-independent activation of p38 
pro-proliferative pathways, inhibiting Smad-dependent signalling with the consequent 
vascular remodelling observed in familial PAH [28, 30, 31]. Indeed, the decline of 
BMPRII function in the endothelium might lead to increased apoptosis favouring the 
development of apoptosis-resistant clones of ECs resulting in the formation of 
plexiform lesion in PH patients [32]. In addition, mice with BMPRII mutations showed 
that loss of BMPRII signalling might induce and/or predispose PH with elevation of 
PAP, wall thickness, pulmonary arterial musculatization and RVH [33, 34].  
In addition, serotonin (5-HT) pathway, which has been related with PASMCs 
hyperplasia, also plays an important role in the development and progression of PH. 
Serotonin transporter is highly expressed in the PASMCs and have been implicated in 
vascular remodelling, since patients with iPAH have increased expression of SERT in 
lung tissues especially in the media of thickened PAs [35]. Furthermore, mice with 
SERT gene knockout developed less severe hypoxia PH than wild-type control and 
selective SERT inhibitors attenuate hypoxia- and MCT-induced PH [36-38]. On the 
other hand, elevated expression of SERT is related with increased severity of PH and 
transgenic mice selectively overexpressing SERT gene in SMCs developed 
spontaneously PH in absence of hypoxia, and overstated PH after exposure to hypoxia 
[39, 40]. Finally, SERT is encoded by a single gene on chromosome 17q11.2 and 
variants in upstream promoter region have been described. The polymorphism consists 
in the insertion or deletion of 44pb, designated the long (L) and the short (S) allele, 
respectively, affecting SERT expression and function. The L-allele induces 2- to 3-fold 
greater level of SERT gene transcription than S-allele [35, 41]. The L/L genotype might 
confer genetic susceptibility to iPAH because this homozygous form is much more 
frequent in these patients (65%) compared with healthy individuals (27%) [35]. 
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Intracellular Ca
2+
 concentration ([Ca
2+
]i) also has been related with pulmonary 
vasoconstriction as well as pulmonary vascular wall thickening and remodelling 
underlying PH. Calcium influx through membrane is controlled by multiple ion 
channels including: i) voltage-dependent Ca
2+
 channel (VDCC) that is regulated through 
changes in membrane potential (Em); ii) receptor-operated Ca
2+
 channels (ROC) which 
is activated by the interaction agonist-membrane receptor; and iii) store-operated Ca
2+
 
channels (SOC) that is activated by depletion of Ca
2+
 from intracellular stores [42]. In 
turn, SOC and ROC function is dependent on the expression of TRP channel genes. 
TRP genes, such as TRPC1, TRPC4, TRPC5, TPRC6 and TPRC7 are expressed in 
human PASMCs, and TRPC1, TRPC3 and TRPC4 are present in PAECs [43, 44]. 
Additionally, TRPCs seems to play a role in PH, since PASMCs of iPAH overexpressed 
TRPC3 and TRPC6 mRNA and protein compared to normal individuals, enhancing cell 
growth and proliferation [43]. Furthermore, it has been reported that a single-nucleotide 
polymorphism in the TRPC6 gene promoter is associated with elevation of [Ca
2+
]i and 
proliferation of PASMCs in 12% of iPAH patients’, predisposing to the disease [45]. 
 
3.2. Neurohumoral Mechanisms 
The primary function of the pulmonary endothelium is to maintain a low PVR through 
the balance between: (i) vasodilators and vasoconstrictors, (ii) mitogens (proliferation) 
and growth inhibitors (apoptosis) and (iii) antithrombotic and prothrombotic 
determinants [46, 47]. In patients with PH, pulmonary endothelial dysfunction appears 
to play an important role in the changes of pulmonary vasculature [48]. Besides 
disorganized proliferation of ECs that lead to the formation of plexiform lesions, these 
cells have an altered production of vasoactive mediators (such as prostacyclin (PGI2), 
nitric oxide (NO), endothelin-1 (ET-1), serotonin (5-HT) and thromboxane (TXA2)) 
affecting vascular tone and SMCs growth which may facilitate the pulmonary vascular 
hypertrophy and structural remodelling (Table 3) [47, 48]. In addition, endothelial 
dysfunction might affect the production of anticoagulant factors altering the balance 
between prothrombotic and antithrombotic determinants, impairing vascular 
homeostasis that can lead to thrombosis and fibrosis [48]. 
  
 
 
 
 
 
Table 3 | Neurohumoral alterations described in the pathobiology of PH 
Mediators 
Physiological Effects Levels in PH 
References Vascular 
Dilatation 
Cell 
Proliferation 
Platelet 
Aggregation 
Apoptosis Serum Lungs 
PGI2      ↓ 
[49-51] 
TXA2       
[49, 50, 52] 
NO      ↓↑ 
[46, 53, 54] 
ET-1     ↑ ↑ 
[55-59] 
5-HT     ↑ ↑ 
[35, 39, 60-62] 
VIP     ↓ ↓ 
[63-65] 
ADM     ↑  
[66, 67] 
ATII      ↑ 
[68-70] 
Ang-1      ↑ [71, 72] 
VEGF      ↑↓ 
[73-77] 
PDGF      ↑↓ 
[78, 79] 
ANP, BNP      ↑ [80-83] 
Apelin      ↓ 
[84, 85] 
Ghrelin       
[86-88] 
Legend: 5-HT, Serotonin; ADM, Adrenomedulin; Ang-1, Angiopoiein-1; ANP, Atrial Natriuretic Peptide; ATII, Angiotensin II; BNP, Brain Natriuretic Peptide ET-1, Endothelin-1; NO, Nitric 
Oxide; PDGF, Platelet-Derived Growth Factor; PGI2, Prostacyclin; TXA2, Thromboxane A2; VEGF, Vascular Endothelial Growth Factor; VIP, Vasoactive Intestinal Peptide;    , no;   , yes; 
↓, decrease; ↑, increase 
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Contraction and relaxation as well as SMCs proliferation and apoptosis are also 
controlled by multiple protein kinases (PKs) (e.g. PKC, Rho kinase) and cyclic 
nucleotides (e.g. 3’-5’-cyclic adenosine monophosphate (cAMP) and 3’-5’-cyclic 
guanosine monophosphate (cGMP)). Indeed, PKA, that can be trigger by PGI2, activates 
KV channels in vascular SMCs promoting vasodilatation [89]. On the contrary, PKC, 
which can be trigger by ATII, ET-1 and TXA2, is able to adjust [Ca
2+
]i mediating 
contraction through activation of Ca
2+
 channels and inhibition of K
+
 channels [90]. PKC 
is also capable to intervene in contraction through phosphorylation of CPI-17 (C-kinase 
potentiated Protein phosphatase-1 Inhibitor) which in turn inhibits myosin light chain 
(MLC) phosphatase (MLCP) increasing MLC phosphorylation [90, 91]. Inhibition of 
MLCP and CPI-17 phosphorylation is also achieved by Rho kinase, also promoting 
smooth muscle contraction [92]. Regarding cAMP role, it is hypothesize that vascular 
relaxation is accomplish by (i) lowering [Ca
2+
] through inhibition of inositol 1,4,5-
triphosphate (IP3) formation due to phospholipase C (PLC) inhibition, (ii) inhibition of 
Ca
2+
 release from sarcoplasmic reticulum, (iii) stimulation of Ca
2+
 uptake and/or 
extrusion, and (iv) inhibition of Ca
2+
 entry [90]. In addition, cAMP through increasing 
MLCP activity and reducing MLC kinase (MLCK), p42/44, MAPK and Rho kinase 
activities can regulate vascular tone [91]. 
Furthermore, [Ca
2+
]i determines smooth muscle contraction, and its rise is the main 
trigger of pulmonary vasoconstriction as well as SMC migration and proliferation, 
leading to pulmonary vascular wall thickening and remodelling. Indeed, [Ca
2+
]i is an 
important second messenger for PASMC migration and proliferation, once some signal 
transduction proteins involved in cellular proliferation are Ca
2+
 dependent (e.g. 
mitogen-activated protein II kinase) [93, 94]. The fact that resting [Ca
2+
]i in 
proliferating PASMC is greater than in growth-arrested cells supports the role of 
enhanced Ca
2+ 
influx into the cytoplasmic space is also essential for cell growth and 
proliferation [95]. Moreover, resting [Ca
2+
]i is higher in PASMCs of iPAH patients than 
in cells of normal individuals, demonstrating once more the role of [Ca
2+
]i in PH [96]. 
In addition, augmentation in [Ca
2+
]i leads to elevation of nuclear Ca
2+
 concentration 
which is essential for cell cycle progression, since at least four steps are sensitive to 
Ca
2+
/CaM (calmodulin) complex activation [97-99]. Additionally, Ca
2+ 
influx via 
VDCC (voltage-dependent Ca
2+
 channels) activates several transcription factors, such as 
CREB (cAMP response element-binding protein), NF-AT (nuclear factor of activated T 
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cells) and NF-κB (nuclear factor kappa B) that are involved in cell proliferation, protein 
synthesis and inflammation [42]. 
 
3.3. Role of Apoptosis 
Although recent therapies target specific cellular and molecular pathways involved in 
the pathogenesis of PAH, they are essentially vasodilators, contributing to symptoms 
relief and improvement but not leading to a better prognosis. So, in the last years 
investigations have been redirected towards a better understanding of the cellular and 
molecular mechanisms underlying vascular remodelling, including the role of apoptosis 
in PH pathogenesis. Indeed, it has been described an imbalance between mitogens and 
growth inhibitors in PH that along with plexiform lesions and neointima formation 
highlight a deregulated apoptosis and cell proliferation in the disease. 
Apoptosis, or programmed cell death, is important for maintenance of tissue 
homeostasis through the elimination of harmful cells. In the vasculature, apoptosis 
modulators are multiple and complex, and might include ROS, NO and ATII systems 
[100-102]. Apoptosis is characterized by cell shrinkage, extensive protein cross-linking 
and chromatin condensation (pyknosis) and migration to nuclear membrane [103-105]. 
In a later stage, although cell membrane remains intact, there is DNA fragmentation 
(karyorrhexis) into 180 to 200 base pairs promoted by Ca
2+
 - and Mg
2+
-dependent 
endonucleases and formation of apoptotic bodies that are quickly removed via 
phagocytosis by surrounding cells [105, 106]. Neither the process of apoptosis nor 
removal of apoptotic bodies is associated with an inflammatory reaction [107, 108]. 
Apoptosis can occur mainly via two main pathways: intrinsic (or mitochondrial) and 
extrinsic (or death receptor) ones (Figure 2). Both pathways converge to the same 
execution pathway that is initiated by the cleavage and activation of execution/effector 
caspases (cysteinyl aspartic acid-proteases) – caspase-3, caspase-6 and caspase-7 – 
resulting in the characteristic alterations previously mentioned [109]. 
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The extrinsic pathway involves the activation of transmembrane death receptors which 
belongs to the TNF (Tumor Necrosis Factor) receptor gene superfamily. These family 
of receptors is characterized for having a similar cysteine-rich extracellular domain and 
a cytoplasmic domain called “death domain” [110]. The best-characterized death 
receptors and corresponding ligands include: i) FasL/FasR, ii) TNF-α/TNFR1, iii) 
Apo3L/DR3, iv) Apo2L (or TRAIL)/DR4 and v) Apo2L (or TRAIL)/DR5 [111]. After 
the ligand bind the death receptor, an adaptor protein (FADD for FasL and TRADD for 
TNF-α) binds through its own death domain to the clustered receptor death domain 
Figure 2 | Apoptosis signalling pathway. Apoptosis can occur mainly via two pathways: intrinsic and 
extrinsic ones. In the extrinsic pathway activation of death receptors activates initiator caspase 8 initiating 
the caspase cascade culminating in apoptosis. The intrinsic pathway is determined by mitochondrial 
permeability which is regulated through the balance between pro-apoptotic and anti-apoptotic mediators. 
Activation of pro-apoptotic ones lead to the release of cytochrome c (cyt c), Smac and Omi promoting 
apoptosis through apoptosome formation and neutralization of inhibitors of apoptosis proteins (IAPs). A 
crosstalk between these two pathways has been described involving, for instance, Bid cleavage by 
caspase 8, releasing cyt c from the mitochondria. 
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[112, 113]. This adaptor protein also has a “death effector domain” that will associate 
with an initiator caspase, such as caspase-8 and caspase-10, through dimerization of the 
death effector domain, activating it by self-cleavage [114, 115]. Then, the initiator 
caspase (caspase-8) trigger execution pathway through activation of downstream 
effector caspase, including caspase-3, culminating in apoptosis [115]. This extrinsic 
pathway can be inhibited trough a protein that binds both initiator caspase and/or 
adaptor protein, such as c-FLIP which can associate with both FADD and caspase-8 
inhibiting apoptosis [116, 117]. 
The intrinsic pathway is determined by mitochondrial permeability which is regulated 
through the balance between pro-apoptotic (Bcl-10, Bak, Bax, Bid, Bad Bim, Bik and 
Blk) and anti-apoptotic (Bcl-2, Bcl-XL, Bcl-XS, Bcl-W and BAG) mediators [109]. 
When the cell is exposed to some stimuli, such as depravation of growth factors, 
exposition to agents that damage DNA or accumulation of unacceptable amounts of 
misfolded proteins, there is the activation of pro-apoptotic mediators (Bax and Bak), 
which translocate into the mitochondria and form channels through which cytochrome c 
(cyt c), Smac/DIABLO, serine protease HtrA2/Omi and other proteins escape to the 
cytosol [118-120]. Released cyt c activates Apaf-1 (apoptotic protease activating factor-
1) and procaspase-9, forming the apoptosome (cyt c/Apaf-1) which is responsible for 
the activation of initiator caspase 9, culminating in the activation of execution pathway, 
via activation of caspase-3 [109, 115]. In addition, it was recently demonstrated that 
besides activating caspases, cyt c can also activate K
+
 channels [121]. Smac/DIABLO 
and HtrA2/Omi have been described to promote apoptosis through the inhibition of IAP 
(inhibitors of apoptosis proteins) activity, such as XIAP [119, 120, 122]. In addition, 
alterations in mitochondrial permeability during apoptosis also lead to the release of 
AIF (apoptosis-inducing factor) and endonuclease G that induce chromatin 
condensation and DNA fragmentation through a caspase-independent cell death [120]. 
A crosstalk between these two pathways was already described involving, for instance, 
Bid cleavage through caspase 8 (Figure 2). Truncanted Bid translocates to the 
mitochondria and causes cyt c release through the homo-oligorization of Bak and/or 
Bax [123-125]. Recently, it was suggested that apoptosis induced by TRAIL (TNF-
related apoptosis-inducing ligand) appears to require the release of mitochondrial 
Smac/DIABLO [126]. TRAIL induces apoptosis through activation of it death 
receptors, DR4 and DR5; only, TRAIL-induced apoptosis requires Bax translocation 
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from the cytosol to the mitochondria. In addition, this translocation of Bax depends on 
the caspase 8 activation and in turn activated caspase 8 cleave Bid, which translocate to 
mitochondria releasing Smac/DIABLO [126]. Considering recent works [127, 128] 
describing TRAIL as a potential therapeutic target in PH, it would be interesting to 
investigate TRAIL in the development of PH and if its administration can also attenuate 
or even reverse vascular remodelling seen in PH. 
Additionally, maintenance of high concentrations of intracellular K
+
 ([K
+
]i) is important 
to the regulation of normal cell volume and suppression of caspases and nucleases [129, 
130]. Therefore, [K
+
]i and K
+
 channels seems to be important in apoptosis modulation. 
Indeed, elevated K
+
 loss or K
+
 efflux through K
+
 channels (via their activation) results 
in reduction of [K
+
]i inducing apoptotic volume decrease and activation of caspases and 
endonucleases that will trigger apoptosis [130, 131]. On the contrary, inhibition of K
+
 
channels maintain sufficient [K
+
]i attenuating apoptotic volume decrease and inhibiting 
apoptosis [131]. Moreover, overexpression of Bcl-2 in rat PASMCs leads to reduction 
of KV channels subunits inhibiting apoptosis [94]. Overexpression of Bcl-2 was also 
found in the lungs of iPAH patients, which might contribute to the downregulation of 
KV channels in these patients [132]. 
In PH, the resistance to apoptosis observed in PASMCs seems to result, in part, from 
the diminished expression of KV channels, since PASMCs from iPAH patients’ present 
reduced mRNA expression of KV channels subunits, probably due to defects in their 
gene transcription [133, 134]. Remillard and colleagues [135] also demonstrated that 
KV1.5 (an α subunit of KV channels) encoding gene of iPAH have multiple single 
nucleotide polymorphisms which probably contributes to altered function and/or 
expression of this channels in PASMCs of patients. Additionally, it is believed that 
certain appetite suppressants (such as aminorex, fenfluramine and dexfenfluramine) are 
associated with an increased risk of PAH, and they appear to contribute to KV channels 
downregulation, leading to PH [136, 137]. In SMCs, BMP inhibits proliferation and 
induces apoptosis, on the other hand in ECs it is responsible for cell survival 
(proliferation) [138, 139]. However, studies had suggested that alterations in BMP axis 
induce PAECs apoptosis [139]. Besides the genetic susceptibility associated to PH due 
to mutation in BMP signalling, initial environmental injuries, such as hypoxia, increase 
flow, inflammation, infections, drugs or toxins, might lead to ECs apoptosis [140-142]. 
Apoptosis of ECs impairs endothelial function providing conditions for an increased 
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proliferation of the remaining endothelium and favouring the emergence of apoptosis-
resistance and hyperproliferative ECs, that are characteristics of PH later stage [140, 
141, 143]. Beyond the release of growth factors and other mediators, the initial 
apoptosis of ECs leaves SMCs more susceptible to these factors that stimulates 
proliferation and inhibits apoptosis of SMCs (Figure 3) [144]. 
 
(adapted from [142]) 
 
3.3.1. Survivin and Smac/DIABLO 
Survivin is the smallest element of the inhibitor of apoptosis protein (IAP) family [145]. 
Along with survivin, seven more IAP proteins were identified in humans: XIAP/hILP 
Figure 3 | Apoptotic-based theory for the development of PH. Although the mechanisms underlying 
PH need to be better characterized, at the moment an apoptotic-based theory for the development of PH 
is one of the most accepted in the scientific community. In addition to the genetic susceptibility 
associated to PH due to mutation in BMP signalling initial environmental factors, such as hypoxia, 
inflammation or drugs, might lead to PAECs apoptosis. The apoptosis of ECs leads to an endothelial 
dysfunction providing conditions that increase proliferation of the remaining endothelium and favouring 
the emergence of apoptosis-resistance, hyperproliferative ECs, expressing survivin, and vasoconstriction, 
that are characteristic of later stage of PH. In addition, beyond induces the release of growth factors and 
other mediators the initial apoptosis of ECs leaves SMCs more susceptible to those factors and all this 
stimulates proliferation and inhibits apoptosis in SMCS. Consequently, the apoptosis resistance and 
proliferation of both PAECs and PASMCs leads to narrowing and occlusion of pulmonary artery 
increasing PVR and PAP, frequently culminating in right-sided heart failure and death. 
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(X-chromosome-linked IAP), C-IAP1/HIAP-2 (cellular inhibitor of apoptosis 1), C-
IAP2/HIAP-1 (cellular inhibitor of apoptosis 2), ILP2 (IAP-like protein 2), MLIAP 
(livin), NAIP (neuronal apoptosis inhibitor protein) and BRUCE [146]. IAP family 
members are characterized by the presence of two to three baculoviral IAP repeat (BIR) 
domains, which can bind and inactivate caspases and prevent caspase-induced 
apoptosis; however, survivin only contains a BIR domain [145, 146]. 
Survivin plays an important role in apoptosis. In response to cell death stimuli, 
mitochondrial survivin is released to the cytosol, inhibiting apoptosis by either directly 
or indirectly interfering with caspase function (Figure 2) [147]. Indeed, it was reported 
that overexpression of survivin suppress apoptosis induced by multiple stimuli 
including TNF and Fas [148-150]. Some authors refer that survivin can directly bind 
and inhibit caspase-3, -7 and -9 activity, since survivin co-immunoprecipitated with 
these, and since apoptosis was suppressed with co-expression of survivin and 
overexpression of caspase-3, -7 and -9 [150]. On the other hand, others demonstrated 
that survivin inhibits apoptosis through the interaction with Smac/DIABLO, which is 
pro-apoptotic factor that promotes caspase activation, binding and inhibiting other IAPs 
activity [151]. By binding with Smac/DIABLO, survivin delays the release of 
Smac/DIABLO into the cytoplasm and increases its cytosolic stability, which results in 
prolonged cell survival [152]. Indeed, Song and colleagues [153] proposed that survivin 
binds Smac/DIABLO released from the mitochondria, decreasing antagonism of 
Smac/DIABLO to XIAP, and therefore the free XIAP directly inhibits caspase and 
consequently apoptosis. Survivin also blocks apoptosis downstream pro-apoptotic 
mediators Bax, Bik, Bak, and cyt c [148, 150]. Furthermore, it was suggested that under 
apoptotic stimuli involving mitochondria, survivin is also able to forms a complex with 
XIAP, enhancing its stability and inhibiting caspases-9 activation [154]. 
Apart from its role in apoptosis, survivin also regulates cell division and viability. 
Survivin seems to have a cell-cycle dependent expression in mitosis, being upregulated 
during G2/M phase of the cell cycle [155]. It was demonstrated to be essential in 
karyokinesis and cytokinesis through the formation of chromosomal passenger complex 
along with Aurora B kinase, INCENP and Borealin [156]. Indeed, survivin is necessary 
in multiple points of mitosis through the regulation of spindle assembly checkpoint, 
metaphase spindle formation and microtubule stability [155, 157, 158]. Therefore, 
inhibition of survivin expression/function results in multiple mitotic defects due to cell 
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cycle arrest, formation of aberrant multipolar spindles, absence of cytokinesis and 
development of multinucleated polyploidy cells [155, 157, 159]. 
BIRC5, the gene that encodes survivin, produces five major isoforms of the transcript 
through alternative splicing of survivin pre-mRNA: survivin (wild type), survivin-2B, 
survivin-ΔEx3, survivin-3B and survivin-2α. Survivin-2α seems to support the 
induction of apoptosis, while survivin (wild type), survivin-3B and survivin-ΔEx3 seem 
to be cytoprotective [160-163]. Some isoforms, such as survivin-3B, appears to also be 
implicated in cell cycle regulation [163]. It has been hypothesised that the dual role of 
survivin might be related with its different compartimentalization. Although nuclear 
survivin is associated to the regulation of cell division, mitochondrial survivin is linked 
to the inhibition of apoptosis, preventing the  activation of effectors caspases which 
confers resistance to apoptosis [147, 154, 164]. On the contrary, survivin released to the 
cytoplasm after apoptosis initiation, loses its protective ability against apoptosis, 
probably due to posttranslational modifications [154, 165]. In a study [166] realized in 
HeLa cells it was demonstrated that differential ablation of survivin through RNA 
interference influences cell death. Partial reduction of the cytosolic pool of survivin 
through RNA interference in association to UVB irradiation resulted in the increased 
catalytic activity of caspases-3/-7 as well as in the proteolytic cleavage of caspase-9. On 
the other hand, loss of mitochondrial membrane permeability and spontaneous apoptosis 
were observed after complete removal of cytosolic survivin. In the same study [166] it 
was verified that preferential suppression of the nuclear pool of survivin culminated in 
cell arrest followed by re-entry into the cell cycle and polyploidy along with other 
mitotic defects. 
In the last years, PAH has been considered a cancer like disease since almost 
characteristics that defines cancer, such as deregulation of growth pathways, 
angiogenesis, dysfunctional KV channels, loss of expression of PGI2 synthase gene 
(anti-proliferative) and augmentation of survivin expression have been associated in the 
disease [167-170]. Indeed, survivin is practically undetectable in differentiated adult 
tissues, but is highly expressed is the most common human cancers, thus making it an 
interesting tumor marker [171]. However, little is known about it expression and role in 
PAH. Until now, it was reported that in an animal model of MCT-induced PH with 
vascular remodelling and PAs of patients with PH survivin was found overexpressed 
and was related with the inhibition of apoptosis and stimulation of PASMCs 
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proliferation [121]. Moreover, lung transfer of survivin gene in experimental animals 
resulted in pulmonary vascular remodelling while adenoviral gene therapy with a 
mutant survivin reversed MCT-induced PH through the activation of KV channels, 
induction of apoptosis and suppression of proliferation [121]. Therefore a better 
characterization of survivin involvement in the development and progression of PAH 
will potentially open new perspectives on the treatment of PAH. 
 
4. Animal Models for the Study of PAH 
Animal models have allowed the study of the pathogenesis and therapeutic strategies of 
multiple diseases, including PAH [172]. Although an animal model should mimic the 
combine characteristics of human disease, including relevant clinical, hemodymanic, 
biochemical and histopathological features, until now no model is able to mimic all 
features of the PAH [173]. Different animal models have been used to study the distinct 
features of PAH, namely the various underlying genetic and environmental causes.MCT 
and chronic hypoxia are the most frequently used animal models in the study of PH 
[172]. In addition, transgenic and knockout models have been used to evaluate altered 
expression of specific genes in the development and/or progression of PH [174, 175]. 
MCT model has been used for over than 50 years, however the molecular mechanisms 
underlying MCT-induced PH need to be better clarified [176]. 
 
4.1. Monocrotaline Animal Model of PAH 
Monocrotaline (MCT) (or 12β,13β,-dehydroxy-12α,13α,14α-trmethylcrotal-1-enine) is 
an 11-membered macrocyclic pyrrolizidine alkaloid derived from the stems, leaves and 
seeds of the Crotalaria spectabilis  that can be administrated by intraperitoneal (60 
mg/kg), subcutaneous (60 mg/kg) or intravenous injection (1-5mg/kg). Although when 
topically or injected applied it does not cause localized toxicity, MCT is known for its 
hepatic and cardiopulmonary toxicity, causing lesions in multiple organs after 
absorption and hepatic bioactivation [15, 177]. In fact, it was described that in chronic 
exposure or single high doses injections of MCT causes periacinar hepatic necrosis, 
hepatocyte necrosis, hepatocellular megalocytosis and hepatic fibrosis [178]. However, 
a single lower-dose injection does not cause hepatic pathology but results in PH after 
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hepatic bioactivation [178, 179]. In the liver, MCT is activated and converted to reactive 
metabolites by cytochrome P450 3A, including dehydromonocrotaline also called 
monocrotaline pyrrole (MCTP) [179]. It is considered that MCTP metabolite is 
responsible for the toxicity and injuries associated to MCT, since intravenous 
administration of chemically synthesized MCTP results in lung and/or liver lesions 
similar to those caused by MCT [15, 179, 180]. 
It is believed that pulmonary vascular endothelium is the early target of MCT injury 
probably due to circulatory proximity to the liver and because lungs are the major 
vascular bed after the liver [179, 181]. In fact, within 7-14 days it was verified increased 
DNA synthesis and hypertrophy of ECs that occurs after an initial induction of ECs 
apoptosis within 4 days pos-injection of MCT [181-184]. As early as 4h after injection 
platelet thrombi can be detected in small arteries, and 4 days pos-injection there is an 
augmentation in the number of swollen mitochondria as well as ROS generation, which 
might be endothelial-toxic [184-186]. At day 7, it has been described an early 
perivascular mononuclear inflammation in MCT-treated rats, mainly due to 
accumulation of macrophages in the adventitia [187, 188]. MCT treatment also causes 
the augmentation of extracellular space in the adventitia, probably due to accumulation 
of oedema fluid from altered microvascular EC permeability [178]. By 8 days after 
MCT injection there is extension of SMCs into peripheral normally non-muscular small 
PAs [189]. By 12 days it was described medial hypertrophy of small arteries with a 
concomitant increase in PAP and resistance [185, 190]. Only after 21 days of MCT 
injection RVH and dysfunction has been described [190, 191]. Unfortunately, there is 
evidence that MCT treatment causes myocarditis affecting both right and left ventricles, 
which will complicate the study of RVH/failure frequently associated with severe PH 
[192]. In addition, MCT treated rats do not developed plexiform lesions, a characteristic 
of later stages of human PH [193]. However, combined treatment of MCT with 
pneumonectomy revealed the development of plexiform lesions [194]. 
Finally, MCT is also able to induce multiple cellular and molecular alterations at all 
layers of pulmonary vessels. Lungs of rats exposed to MCT present increased 
expression of multiple pro-inflammatory cytokines [195-197]. In addition, after MCT 
treatment it was described an increase of medial SERT and survivin expression, 
whereas KV channels expression, including KV 1.5 and KV 2.1, were diminished [37, 
121, 198]. BMPRII expression along with its signalling pathway is reduced in MCT-
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treated rats, however its restoration does not improve PH [199, 200]. At intima level, 
MCT cause an augmentation in endothelial expression of ET-1 with a downregulation 
of ETB (endothelin receptor type B) and eNOS (endothelial nitric oxide synthase) 
expression [201, 202]. In the adventitial layer there is an enhancement of ECM 
glycoproteins production, such as elastin, fibronectin, collagen and tenascin-C [203, 
204]. 
Taken together, MCT-induced PH differs in some aspects of human PAH, but mimics 
several of its features, such as hemodynamic repercussions, histological alterations and 
high mortality. In comparison with other models of PH, MCT model offers technical 
simplicity, reproducibility and low cost, reasons that justify its general use in the 
investigation of PH [205]. 
5. Treatment 
Until approximately 25 years ago, PAH was considered a fatal disease with poor 
survival, being its treatment only palliative [4]. The therapies were based on 
symptomatic relief and were adapted from other pulmonary and cardiac diseases and 
included oxygen supplementation, anticoagulants, diuretics, digoxin, inotropes and 
calcium-channel blockers (CCB) (Table 4) [206]. However, the intense research 
dedicated to the pathobiology of PAH has been helpful for the development of several 
disease-specific therapies. In fact, treatments targeting specific cellular and molecular 
pathways involved in the pathogenesis of PAH have being implemented and they 
allowed symptoms improvement and increased survival (Table 4) [207]. Despite 
slowing the progression of the disease, treatments do not lead to a cure but diminished 
the need of surgical procedures (e.g. heart/lung transplantation and atrial septostomy), 
performed in patients who fail to respond to the pharmacologic therapy [208-211]. As 
summarized in Table 4, current treatments include: i) supportive therapies, ii) calcium-
channel blockers, iii) synthetic prostacyclin and prostacyclin analogues, iv) endothelin-1 
receptor antagonists, v) type 5 phosphodiesterase inhibitors and vi) interventional 
procedures. 
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Table 4 | Current therapies for PAH 
Drug Route 
Comments and 
recommendations 
Adverse effects and 
contradictions 
References 
Supportive therapies 
Anticoagulants O 
Improved survival in small 
retrospective studies 
Bleeding [206, 207, 
212] 
Diuretics O 
Used to reduce fluid retention, 
indicated for RV volume 
overload 
Hypotension 
Oxygen In Useful in patients with hypoxia  
Digoxin O 
Used for RV failure with benefit 
on RV function 
Vomiting, arrhythmias 
Inotropes IV 
Mostly applied for end-stage 
RV failure 
Tachycardia 
Calcium-channel blockers 
Nifedipine O Helpful as long term in patients 
with acute vasodilator 
responsiveness 
Peripheral oedema, 
hypotension 
[206, 213] 
Diltiazem O 
Amlodipine O 
Synthetic prostacyclin and prostacyclin analogues 
Epoprostenol cIV 
Can have beneficial effects for 
years, used in combination 
therapy 
Nausea, diarrhoea, 
headache, jaw pain, 
flushing, catheter-
related 
sepsis/thrombosis 
[207, 214-
220] 
Treprostinil 
SC, O, 
IV, In 
Used when oral therapy has 
failed; short-term benefits 
Nausea, diarrhoea, 
rash, headache, 
infusion site pain 
Berapost O 
Short-term benefits; used in 
combination therapy 
Flushing, headache 
Iloprost In, IV 
Short-term benefits; used in 
combination therapy 
Headache, jaw pain, 
cough, flushing 
Endothelin-1 receptor antagonists 
Bosetan O 
Dual ETA/ETB antagonist, used 
as a fist-line drug; short-term 
benefits,; used in combination 
therapy 
Headache, anaemia, 
oedema, hepatotoxicity 
[207, 221, 
222] 
Sitaxsentan O 
Selective ETA receptor 
antagonists 
Flushing, 
hepatotoxicity, INR 
augmentation, warfarin 
interaction 
Ambrisentan O 
Flushing, 
hepatotoxicity 
Type 5 phosphodiesterase inhibitors 
Sildenafil O 
Used as an initial agent and in 
combination therapy 
Headache, visual 
disturbances, nasal 
congestion 
[207, 223, 
224] 
Tadafil O  
Nausea, headache, 
dyspnea 
Interventional procedures 
Atrial 
septostomy 
 
Decompresses right heart, 
improves systemic output 
 
[206, 207, 
211] 
Lung 
transplantation 
 
Improves survival and quality of 
life 
 
Legend: cIV, continuous intravenous; In, inhaled; INR, international normalized ratio; IV, intravenous; O, oral; RV, 
right ventricle; SC, subcutaneous. 
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In addition to monotherapy, combination therapy has been an attractive option since it 
permits to target more than one pathophysiological mechanisms of PAH, allowing the 
improvement of clinical efficiency and minimizing side-effects [225, 226]. The main 
clinical combination therapy being considered includes: i) prostanoids and endothelin-1 
receptor antagonist (e.g. bosentan + iloprost, bosentan + beraprost, bosentan + 
epoprostenol), ii) prostanoids and type 5 phosphodiesterase inhibitors (e.g. sildenafil + 
epoprostenol, sildenafil + iloprost, sildenafil + berapost, sildenafil + treprostinil) and iii) 
type 5 phosphodiesterase inhibitors and endothelin-1 receptors antagonists (e.g. 
bosentan + sildenafil, bosentan + tadafil) [227-233]. Finally, with increasing studies on 
the pathobiology of PAH multiple potential therapeutic targets have been suggested: i) 
Rho kinases inhibitors (fasudil), ii) tyrosine kinase inhibitors (imatinib), iii) stimulators 
and activators of soluble guanylate cyclase (riociguat), iv) VIP, v) ADM, vi) HMG-CoA 
reductase inhibitors (statins such as simvastatin) and vii) angiotensin II type 1 receptor 
antagonists (losartan)) [66, 234-243] . These potential therapeutic targets were or are 
being studied in patients with PAH and/or experimental models of the disease. 
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Vascular remodelling is an important event in the progression of PAH, characterized by 
an excessive cellular proliferation and a reduced apoptosis; however, little is known 
about the molecular events underlying the imbalance between cellular proliferation and 
apoptosis. So, the aim of the present work was to study the contribution of apoptosis to 
the pathogenesis of PAH, through the analysis of the apoptotic proteins survivin and 
Smac/DIABLO, in an animal model of MCT-induced PAH. To achieve this goal, 
morphometric analysis of heart and lungs of controls and animals with MCT-induced 
PAH was related with the pulmonary and cardiac expression of survivin and 
Smac/DIABLO, evaluated by immunohistochemistry and western blot. 
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1. Experimental Design 
In order to study the contribution of apoptosis to the pathogenesis of PAH, an 
experimental protocol was designed and is summarized in Figure 4. 
 
 
 
 
Figure 4 | Experimental protocol design (sc, subcutaneous injection) 
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2. Animal Protocol 
Animal experiments were performed according to the Portuguese law for animal 
welfare (DL 129/92, DL 197/96; P 1131/97) and conform to the National Institutes of 
Health Guide for the Care and Use of Laboratory Animals (NIH Pub. No. 85-23, 
Revised 1996). Male Wistar rats (Charles River Laboratories, Barcelona, Spain) 
weighing 180-200g were housed in groups of 5 rats/cage, in a controlled environment 
under a 12:12-h light-dark cycle at room temperature of 22ºC, with free supply of food 
and water. Rats randomly received a subcutaneous injection of MCT (60 mg/kg, Sigma-
Aldrich, Barcelona, Spain) (MCT group, n=10 per time point) or an equal volume of 
vehicle (1 mL/kg of saline) (Sham group, n=10 per time point). 
 
 
3. Hemodynamic Analysis 
In order to evaluate and confirm the presence and progression of the disease, 
hemodynamic assessment was performed 7 and 21 days after MCT/vehicle injection. 
The rats were anesthetized by inhalation of a mixture of sevoflurane (4%) and oxygen, 
intubated for mechanical ventilation (Dual Mode, Kent Scientific, Connecticut, USA) 
and placed over a heating pad (body temperature is maintained at 37°C). Under 
binocular surgical microscopy (Wild M651.MS-D, Leica; Herbrugg, Switzerlad), the 
right jugular vein was cannulated for fluid administration (prewarmed 0.9% NaCl 
solution) to compensate for perioperative losses. The heart was exposed by a median 
sternotomy and the pericardium was widely opened. Right ventricular hemodynamic 
function was measured with pressure-volume (PV) catheter (PVR-1045, Millar 
instruments, Houston, USA). Data was continually acquired (MPVS 300, Millar 
Instruments, Houston, USA) and digitally recorded at 1000Hz (ML880 PowerLab 
16/30, Millar TM instruments, Houston, USA). After complete instrumentation, the 
animal preparation was allowed to stabilize for 15 minutes. Hemodynamic recording 
were made under basal with respiration suspended at end-expiration. Heart rate (HR) 
and RV peak systolic pressure (Pmax) were obtained and analysed using PVAN 3.5 
(Millar Instruments, Houston, USA). 
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4. Tissue Preparation for Morphometric, Immunohistochemistry and 
Molecular Analysis 
The heart, lungs and right gastrocnemius muscle were excised and weighted. The right 
tibia was also excised and its length was measured with a millimetric ruler. Under 
binocular magnification (3.5), the RV free wall was dissected from the left ventricle 
(LV) + septum (S) and weighted separately. Heart, lungs, RV and LV + S weights were 
normalized to body weight (BW) and gastrocnemius weight was normalized to tibia 
length. Samples from RV, LV and lung were fixed and included in paraffin for light 
microscopy, or frozen with liquid nitrogen for molecular studies. 
 
5. Morphometric Analysis 
Samples of RV, LV (midway between the apex and base) and lung were fixed in 4% 
(v/v) buffered paraformaldehyde followed by dehydration with graded ethanol, 
diaphanization with xylene and included in paraffin blocks. Serial sections (4 µm of 
thickness) of paraffin blocks were cut by a microtome (RM2125RTS, Leica, Nussloch, 
Germany) and mounted on silane-coated slides. The slides were dewaxed in xylene and 
hydrated through graded alcohols. Sections were stained for haematoxylin-eosin by 
immersing slides in Mayer’s haematoxylin solution for 5 minutes followed by 
immersion in aqueous eosin solution for 5 minutes. Slides were still submitted to graded 
alcohols and xylene and mounted with Entellan. Studied samples were observed at light 
microscopy (Dialux 20, Leitz, Wetzlar, Germany), photographed with a digital camera 
(XC30, Olympus, California, USA) and measured with a digital image analyzer (cell^B 
life science basic imaging software, Olympus, California, USA). Five images with 
random microscopic fields (magnification of 400) were obtained from each section to 
compensate for variations within sections. Only round to ovoid muscle fibbers with a 
nuclear profile were counted to measure the cardiomyocytes surface area (CSA). 
Around 500 cardiomyocytes per group per time point were analyzed. On pulmonary 
specimens, external diameter and medial wall thickness in muscular arteries (20-25 
arteries/lung) were analyzed. Orthogonal intercepts were used to generate eight random 
measurements of external diameter (distance between the external lamina) and sixteen 
random measurements of medial thickness (distance between the internal and external 
lamina). For each artery medial hypertrophy was expressed as follows: % wall thickness 
= [(medial thickness   2) / (external diameter)]   100. 
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6. Immunohistochemistry 
Immunohistochemistry was performed to determine survivin and Smac/DIABLO 
expression in the RV. Sections (4 µm) were placed on SuperFrost®Plus slides (Thermo 
Scientific, Massachusetts, USA). After deparaffinization and rehydration, slides were 
subjected to heat induced antigen retrieval by immersion in 10 mM sodium citrate 
buffer (pH 6.0) in the microwave for 30 minutes. Peroxidase activity was blocked by 
3% hydrogen peroxide for 10 minutes. Blockage of non-specific binding was performed 
with 5% normal goat serum (G9023-10mL, Sigma-Aldrich, Barcelona, Spain) in TBS-T 
(100 mM Tris, 1.5 mM NaCl, pH 8.0; 0.1% Tween-20) for 1 hour at room temperature 
flowed by 15 minutes of washes in TBS-T. Sections were encircled with a pap pen 
(Vector Laboratories, California, USA) to prevent splitting leakage of the flowing 
incubation solutions. Endogenous avidin-biotin expression was blocked using an 
endogenous avidin + biotin blocking system (ab3387, abcam, Cambridge, UK) 
according to manufacturer’s instructions, being  followed by incubation with the 
primary antibodies (1:500 dilution; rabbit anti-Survivin (ab469, abcam, Cambridge, 
UK) or dilution 1:250; rabbit anti-Smac/DIABLO (ab8115, abcam, Cambridge, UK)) 
overnight at 4°C. After incubation with primary antibodies, slides were washed 3 times, 
5 minutes each with TBS-T and incubated with goat anti-rabbit IgG secondary antibody 
(1:250 dilution; ab6720, abcam, Cambridge, UK) for 2 hours at room temperature. 
Slides were submitted to another 3 washes in TBS-T prior being incubated with 
Streptavidin protein, HRP (1:1000 dilution; ab7403, abcam, Cambridge, UK). To 
visualize the peroxidase activities in sections 3,3-diaminobenzidine (DAB, ab94665, 
abcam, Cambridge, UK) was used. Finally, slides were counterstained with Mayer’s 
haematoxylin, submitted to graded alcohols and xylene and mounted with Entellan. 
Negative control reactions included omission of the primary antibody. The slides were 
observed and photographed with a microscope (Dialux 20, Leitz, Wetzlar, Germany) 
under 400 magnification. Survivin and Smac/DIABLO expression was qualitatively 
determined as positive (cytoplasmatic staining) or negative in around 500 
cardiomyocyte per group per time point. 
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7. Western Blot 
RV, LV and lung samples (n=6 per group per time point) previously frozen with liquid 
nitrogen were homogenised in phosphate buffer (13 mM KH2PO4, 54mM NaHPO4, pH 
7.4) (in the proportion of 1:20) with a Bio-Gen PRO200 homogeniser (Pro 200, Pro 
Scientific, Connecticut, USA). Total protein concentration was spectrophotometrically 
determined with the colorimetric method RC-DC protein assay (Bio-Rad, California, 
USA). The optic density was determined at 750nm in a microplate reader (UVM340, 
Asys, Cambridge, UK). Simultaneously, a calibration curve was performed using 
different concentrations of bovine serum albumin (BSA). 
Equivalent amounts of total protein from the homogenised RV, LV and lung of each 
group were electrophoresed on a 12.5 % SDS-PAGE at 200 V at room temperature as 
described by Laemmli [244]. Proteins were electrotransfered to a nitrocellulose 
membrane (0,2 µm, Bio-Rad, California, USA) in 25 mM Tris, 192 mM and 20 % 
methanol at 200 mA. Successful transfer was confirmed by staining the membranes 
with Ponceau S. Nonspecific binding sites were blocked with 5 % (w/v) dry non-fat 
milk in TBS-T (100 mM Tris, 1.5 mM NaCl, pH 8.0 (TBS) and 0.5 % Tween 20). 
Membranes were incubated with primary antibody (rabbit anti-Survivin (ab469, abcam, 
Cambridge, UK), 1:1000 dilution or rabbit anti-Smac/DIABLO (ab8115, abcam, 
Cambridge, UK), 1:500 dilution) overnight at 4°C with agitation. Afterwards, blots 
were washed in TBS-T, incubated with a secondary antibody (LI-COR IRDye® 
800CW, Nebraska, USA) and washed in TBS-T. Immunoreactive bands were observed 
under fluorescence using an Odyssey system (LI-COR Odyssey, Nebraska, USA) and 
the results were analysed with Quantity One software v. 4.6.3 (Bio-Rad, California, 
USA) 
 
8. Statistical Analysis 
Statistical analysis was performed using GraphPad Prism software v. 5.0 (GraphPad 
Software, California, USA). All data are presented as mean ± SEM and were compared 
using Two Way ANOVA. When treatments were significantly different, Students-
Newman Keuls post-hoc test was selected to perform pairwise multiple comparisons. 
Results were considered significantly different when p<0.05. 
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1. Hemodynamic Evaluation and Morphometric Analysis 
In order to confirm and evaluate RV dysfunction and the development of PAH through 
MCT injection, hemodynamic evaluation and morphometric analysis were performed 7 
and 21 days after MCT injection. As represented in Table 5, at D7 no significant 
hemodynamic alterations were noted. However, at D21, RV peak systolic pressure in 
the MCT treated group was significantly enhanced when compared with Sham group. 
 
 
Table 5 | Hemodynamic evaluation of MCT-induced PAH. 
 D7 D21 
Sham MCT Sham MCT 
Heart rate (bpm) 349 ± 22 357 ± 10 340 ± 14 376 ± 23 
RV Pmax (mmHg) 27.3 ± 2.2 31.5 ± 1.5 26.3 ± 1.2 38.9 ± 2.7 
* 
Data are present as mean ± SEM. Sham, sham group; MCT, monocrotaline group; Pmax, peak systolic 
pressure; RV, right ventricle. 
*
p < 0.05 vs Sham of the same day 
 
 
 
Table 6 | Morphometric alterations in MCT-induced PAH 
 
D7  D21 
Sham MCT  Sham MCT 
Body weight (g) 230.4 ± 8.2 214.6 ± 3.2  290.6 ± 4.5 
a 
260 ± 4.9 
*, a 
HW/BW (g/Kg) 3.031 ± 0.079 3.129 ± 0.061  2.794 ± 0.069 3.282 ± 0.113 
* 
RV/(LV+S) (g/g) 0.282 ± 0.017 0.332 ± 0.021  0.302 ± 0.012 0.467 ± 0.049 
*, a 
RV/BW (g/Kg) 0.583 ± 0.038 0.332 ± 0.021  0.584 ± 0.013 0.911 ± 0.095 
*, a 
(LV+S)/BW (g/Kg) 2.070 ± 0.058 2.011 ± 0.047  1.957 ± 0.060 1.956 ± 0.042 
L/BW (g/Kg) 5.436 ± 0.307 5.896 ± 0.400  4.782 ± 0.323 7.241 ± 0.464 
*, a 
G/tib (g/cm) 0.382 ± 0.012 0.374 ± 0.004  0.440 ± 0.016 0.430 ± 0.008
 
Data are present as mean ± SEM. Sham, Sham group; MCT, monocrotaline group; HW, heart weight; 
BW, body weight; RV, right ventricle; LV+S, left ventricle plus septum; L, lungs; G, gastrocnemius; tib, 
tibia. 
*
p < 0.05 vs Sham of the same day; 
a 
p < 0.05 vs D7 of the same treatment group. 
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The morphometric alterations registered in MCT-induced PAH are summarized in Table 
6. At day 21, animals from the MCT group evidenced a significant body weight loss in 
comparison to the Sham group. There was a significant augmentation of body weight in 
both groups between days 7 and 21. In addition, there were no significant alterations in 
the ratio G/tib. 
In MCT treated animals, lung weight increased between time-points, and was 
significantly higher in MCT group than in Sham group. As expressed in Figure 5, at 
D21 media of pulmonary artery is significantly hypertrophied in MCT-treated animals 
comparing with Sham group.  
The ratio HW/BW was significantly higher in MCT-treated animals compared to Sham 
on day 21 after injection. Moreover, RV/(LV+S) and RV/BW indexes were both 
significantly increased on day 21 in MCT-treated animals, indicating that these ones 
developed RV hypertrophy. Also, as expressed in Figure 5, MCT-treated animals 
developed cardiomyocytes hypertrophy since D7. The RV hypertrophy increased with 
the progression of the disease since RV cardiomyocytes cross sectional area was 
significantly higher on day 21 than on day 7. There were no differences in the 
(LV+S)/BW parameter in both MCT and Sham groups. 
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Figure 5 | Pulmonary arterial and right ventricular cardiomyocyte hypertrophy. A and C: 
Histological appearance of small pulmonary arteries and right ventricular cardiomyocytes, respectively, 
stained with hematoxylin and eosin of Sham and MCT groups 7 and 21 days after injection. B: Medial 
layer thickness expressed as percentage of all thickness. D: Right ventricular cardiomyocytes 
hypertrophy expressed as cardiomyocytes cross-sectional area (µm
2
). Data are present as mean ± SEM. 
Sham, Sham group; MCT, monocrotaline group. 
*
p < 0.05 vs Sham of the same day; 
a 
p < 0.05 vs D7 of 
the same treatment group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.  Survivin and Smac/DIABLO Expression 
With the aim to study the role of apoptosis in PAH, the expression of survivin and 
Smac/DIABLO were analysed in RV, LV and lungs. 
Survivin and Smac/DIABLO expression in RV were analysed through 
immunohistochemistry and western blot, and the results are shown in Figure 6 and 
Figure 7, respectively. MCT treatment significantly raised survivin expression in both 
day 7 and 21 after injection as compared with Sham group. Sham groups did not present 
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any alterations in survivin expression. Contrarily, MCT treatment significantly 
decreased Smac/DIABLO expression in comparison with Sham groups. As present in 
Figure 8, MCT treatment has induced an increase in survivin levels ans a decresed in 
Smac/DIABLO levels in LV, in a similar way of those noted in RV. 
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Figure 6 | Right Ventricle survivin expression, evaluated through immunohistochemistry and western 
blot. A: Representative image of immunohistochemistry for survivin expression in the right ventricle of 
Sham and MCT groups 7 and 21 days after injection. B: Survivin expression in right ventricle expressed as 
percentage of stained cardiomyocytes in immunohistochemistry. C: Right ventricle survivin expression 
evaluated through western blot with a representative image of the results. Data are present as mean ± SEM. 
Sham, Sham group; MCT, monocrotaline group; RV, right ventricle. 
*
p < 0.05 vs Sham of the same day; 
a 
p 
< 0.05 vs D7 of the same treatment group.  
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Figure 7 | Smac/DIABLO expression in right ventricle, evaluated through immunohistochemistry and 
western blot. A: Representative image of immunohistochemistry for Smac/DIABLO expression in the right 
ventricle of Sham and MCT groups 7 and 21 days after injection. B: Smac/DIABLO expression in right 
ventricle expressed as percentage of stained cardiomyocytes in immunohistochemistry. C: Right ventricle 
Smac/DIABLO expression evaluated through western blot with a representative image of the results. Data 
are present as mean ± SEM. Sham, Sham group; MCT, monocrotaline group; RV, right ventricule. 
*
p < 
0.05 vs Sham of the same day; 
a 
p < 0.05 vs D7 of the same treatment group. 
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Figure 8 | Survivin (A) and Smac/DIABLO (B) expression in left ventricle, evaluated through western 
blot of Sham and MCT groups 7 and 21 days after injection, with respective representative images. Data 
are present as mean ± SEM. Sham, Sham group; MCT, monocrotaline group. 
*
p < 0.05 vs Sham of the 
same day; 
a 
p < 0.05 vs D7 of the same treatment group. 
Figure 9 | Lung survivin (A) and Smac/DIABLO (B) expression, evaluated through western blot of 
Sham and MCT groups, 7 and 21 days after injection, with respective representative images. Data are 
present as mean ± SEM. Sham, Sham group; MCT, monocrotaline group. 
*
p < 0.05 vs Sham of the same 
day; 
a 
p < 0.05 vs D7 of the same treatment group. 
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In respect to lung (Figure 9), survivin expression was significantly augmented in MCT 
groups. However, in MCT-treated animals, between day 7 and 21 after injection, there 
was a significant reduction of survivin expression, while no differences were noted 
between Sham groups. In contrast, pulmonary Smac/DIABLO expression significantly 
lowered with MCT treatment in both time-points in comparison with Sham groups. 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VI – Discussion 
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PAH is a multifactorial, progressive disease with substantial mortality and morbidity. 
Over the years, cellular and molecular mechanisms underlying PAH have been studied 
in order to better understand PAH pathogenesis as well as to develop therapies that 
might lead to a better prognosis. Thus, studies focusing the development, progression 
and treatment of PAH are still essential. Most of the research performed with animal 
models of this disease has been focused on advanced stages of the disease (25-35 days 
after MCT injection), being scarce the ones conducted in the early phases, probably 
reflecting the fact that most patients with PAH are usually diagnosed at advance stages. 
We believe that the study of PAH in early stages will allow a better understanding of 
pathophysiologic pathways that might be therapeutically modulated aiming to cure 
PAH. For that reason, the present study analysed the role of apoptosis in two time-
points of disease progression in a well characterized animal model of MCT-induced 
PAH.  
MCT administration affects mainly hepatic and cardiopulmonary systems, promoting 
vasoconstriction, ECs hypertrophy, SMCs hypertrophy and hyperplasia and 
inflammation at lung level and also RV hypertrophy [15, 182, 193]. Several studies 
reported that, in rats, the severity of these lesions depends on MCT dose, administration 
route and the animal age at the time of treatment [180, 245]. Although, not all the 
typical findings of human PAH are mimicked by this animal model (such as plexiform 
lesions present in human PAH and absent in the experimental model), it has identical 
hemodynamic and some morphological features, like pulmonary artery medial layer 
remodelling and RV hypertrophy, which are the focus of our study [15, 193]. Our 
results, showed that MCT treatment, after 21 days, induced an augmentation of RV 
peak systolic pressure (Table 5) in association with increased RV mass (Table 6) and 
cardiomyocyte hypertrophy (Figure 5), confirming the previous studies. Also, as 
described before, our results demonstrated that MCT injection promoted pulmonary 
arterial wall thickness (Figure 5), which is the primary cause of pressure overload, 
leading to the increase of PVR and PAP and consequently RV hypertrophy. Therefore, 
RV hypertrophy seems to reflect a compensatory response in which RV adapts to the 
sustained afterload elevation [21, 246]. Interestingly, although there were no 
hemodynamic neither morphological alterations (Table 5 and Table 6, respectively) at 
RV, our results demonstrated for the first time that cardiomyocytes were hypertrophied 
at day 7 after MCT injection (Figure 5). These results suggest that besides heart 
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overwork due to pulmonary hypertrophy and PVR, other mechanisms, such as 
neurohumoral ones, might lead to RV hypertrophy. 
In the last years, angiogenesis, dysfunctional KV channels, loss expression of 
prostacyclin synthase gene (anti-proliferative), deregulation of growth signalling 
pathways and augmentation of survivin expression (anti-apoptotic) have been observed 
in the development and/or progression of PAH [167-170]. In order to evaluate the 
contribution of survivin pathway to PAH pathogenesis, we evaluated the cardiac and 
pulmonary expression of this anti-apoptotic protein as well as of its antagonist, 
Smac/DIABLO. In 2008, a study carried out by Levkau and colleagues [159] revealed 
several key features of survivin in the heart. They demonstrated that in the neonatal 
period, mice deficient for cardiac survivin presented a decrease number of total 
cardiomyocytes and a marked cardiomyocytes polyploidy due to multiple rounds of 
DNA replication without cytokinesis. This altered phenotype led to progressive heart 
failure and ultimately to death. In the same study survivin overexpression was 
associated with the induction of cell division and the protection of cardiomyocytes from 
doxorubicin-induced apoptosis. Moreover, they found only residual levels of survivin in 
normal human heart, but these were extraordinarily increased in the heart of patients 
with end-stage of heart failure. Interestingly, hemodynamic support with LVAD (left 
ventricular assist device) resulted in a marked reduction of expression of cardiomyocyte 
survivin, raising the hypothesis that cardiac survivin expression is load-dependent 
[159]. Wohlschlaeger and colleagues [247] also described that survivin was 
overexpressed in congestive heart failure but decreased after unloading. They also 
demonstrated a positive correlation between cardiomyocytes survivin expression and 
cardiac hypertrophy and DNA content. In the present study, survivin was significantly 
enhanced at day 7 after MCT injection and progressively increased throughout the 
development of MCT-induced PAH (Figure 6). Moreover, cardiomyocyte hypertrophy 
(Figure 5) was accompanied by increased expression of survivin (Figure 6) both of 
which progressively increased until day 21. LV expression of survivin had a similar 
pattern to RV (Figure 8). These results suggest that survivin might be involved in the 
cardiac remodelling process underlying PAH. Previously, McMurtry and colleagues 
[121] also demonstrated that lung survivin overexpression preceded hemodynamic 
alterations verified in the disease. Our results (Table 5 and Figure 9) corroborate 
McMurtry findings. Therefore, taking into consideration: i) the overexpression of RV, 
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LV and lung survivin at day 7 after MCT injection, ii) the similar survivin expression 
profile between LV and RV, and iii) the occurrence of survivin overexpression before 
hemodynamic alterations, makes us believe that besides pulmonary arterial hypertrophy 
other mechanisms, perhaps neurohumoral ones, are involved in RV hypertrophy. In 
particularly, we hypothesised that pulmonary vascular remodelling phenomena may be 
signalized to RV, possibly through neurohumoral mediators, such as ET-1, ATII, PDGF 
and catecholamines, inducing survivin overexpression and cardiomyocytes hypertrophy, 
a favourable cardiac remodelling response to the disease, as previously suggested [21, 
248]. 
The expression of Smac/DIABLO was the reverse of survivin expression with 
decreasing levels noticed from day 7 to day 21 after MCT administration, in both RV 
and LV as well as in lung (Figure 6, Figure 8 and Figure 9, respectively). Data suggest 
that expression of Smac/DIABLO decreases with the progression of PAH. 
Smac/DIABLO is known for its pro-apoptotic properties through its interaction with 
IAP proteins, including survivin, eliminating their inhibitory effect on caspases [119, 
151, 249]. On the other hand, survivin expression is also able to delay the release of 
smac/DIABLO from the mitochondria, preventing its pro-apoptotic function [152]. 
Several studies also revealed a reciprocal expression of survivin and Smac/DIABLO in 
different types of cancers [250-253]. So, we believe that deregulation in the balance 
between survivin and Smac/DIABLO might be related with pulmonary vascular 
remodelling and cardiomyocytes hypertrophy in response to apoptotic stimuli. 
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Aiming to evaluate the contribution of apoptosis to the pathogenesis of PAH, MCT 
animal model was used to analyse pulmonary and cardiac expression of survivin and 
Smac/DIABLO. Data allowed us to conclude that: 
i) cardiomyocytes hypertrophy was present 7 days after MCT injection, proceeding 
hemodynamic alterations; 
ii) RV and LV survivin overexpression was demonstrated 7 days after MCT injection 
and progressively increased throughout the development of MCT-induced PAH; 
iii) although increased 7 days after MCT injection, lung survivin expression 
progressively decreased between time-points; 
iv) RV, LV and lung Smac/DIABLO expression was upregulated 7 days after MCT 
injection but progressively decreased throughout the development of MCT-induced 
PAH. 
Taken together, data suggest that a deregulation in the balance between survivin and 
Smac/DIABLO might be related with pulmonary vascular remodelling and 
cardiomyocytes hypertrophy in response to apoptotic stimuli. Therefore, we consider 
that a therapy targeting survivin and/or Smac/DIABLO might be a future option for the 
treatment of PAH. 
In the future, we intend to study survivin expression in cellular fractions (nuclear, 
cytoplasmic and mitochondrial) as well as the existence of possible posttranslational 
modifications that regulate cellular location of this protein and, consequently, its 
activity. Data obtained in the present study also leads us to therapeutically target the 
balance between survivin and Smac/DIABLO using terameprocol which is a drug 
widely used in cancers therapeutics. 
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